IO Biotech Q1 EPS $(0.60) Up From $(31.53) YoY
IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.60) per share. This is a 98.1 percent increase over losses of $(31.53) per share from the same period last year.
IO Biotech Reveals Updated Data From IO102-IO103/Opdivo Combo Trial In Melanoma
IO Biotech Inc (NASDAQ: IOBT)
IO Biotech Announces Data From MM1636 Phase 1/2 Clinical Trial To Be Presented At 2022 AACR Annual Meeting
Updated Data as of December 1, 2021 from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab in Metastatic Melanoma
Three-year Survival Probability of 73%
Subgroup analyses including patients with poor
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that moved stocks during the week.
76 Biggest Movers From Yesterday
Gainers
Houston American Energy Corp. (NYSE: HUSA) surged 494.7% to close at $11.30 on Monday amid continued momentum and an increase in the price of oil.
55 Biggest Movers From Yesterday
Gainers
Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday.
58 Biggest Movers From Friday
Gainers
Hagerty, Inc. (NYSE: HGTY) shares jumped 46.5% to close at $15.62.
TuanChe Limited (NASDAQ: TC) gained 44.7% to settle at $3.30.